Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab.
Positive Phase II Data for Peregrine’s Lung Cancer Treatment
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.
